Antibody-targeted immunotherapy for treatment of malignancy.
about
Targeting antibacterial agents by using drug-carrying filamentous bacteriophagesCellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell linesTargeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalSelective cell targeting with light-absorbing microparticles and nanoparticles.A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Efficacy, safety, and cost of new anticancer drugs.Combination therapy in combating cancer.Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus.Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.Blood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy.Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.Fibroblast growth factors in cancer: therapeutic possibilities.Radioimmunotherapy with engineered antibodies.Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.Molecular biological design of novel antineoplastic therapies.Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cellsGene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.Perioperative management of medications used in the treatment of rheumatoid arthritis.Role of Fc Receptors as a therapeutic target.Antibody-drug conjugates - a perfect synergy.Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum.Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis.Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G.The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
P2860
Q24548258-9E3E0A11-9617-4BE3-ABA7-152ABC6C3FD2Q24650717-804EA7A4-EE56-41EC-85B3-84E986A69496Q24681992-53DE8898-A1BD-4CE4-B4C5-3B8E9A363147Q30539080-70B84432-86B8-4949-A5A2-C9AE83F6063BQ33200753-C2EBA914-A7F2-4B80-8DED-9B5DCB95EDA2Q33301860-7EF417B6-6EAA-40D5-A099-990AF76C2DF5Q33811454-F99A1EAF-3908-4D11-8DB3-B60CA1115688Q33914234-3826F142-0824-4D33-8925-8EBCA589BE5AQ34168613-F26FBABA-C169-4775-99C9-E236DCAEC7EBQ34452700-9BB75778-47E3-44C9-9018-73CEEA198CB8Q34452719-C1A51F2B-0FB3-4A3C-AE85-6009622DE6EEQ34825919-3AA6ED55-8288-4EEA-B1B5-9BFDF3914385Q34837255-95354E3E-FEF1-4A0D-B304-5C1136D902FCQ35681517-6E8FB60F-D0A4-4D85-BA28-DC777D566FB3Q35689463-F86021DC-1683-446D-B9FA-F92B4AD09D9BQ35790781-6D5F5EE9-B20D-4AAC-89AC-FCA5DB3A4D63Q36079223-7153B106-90D1-490E-BC30-6CA53874376DQ36347760-9FBD3D42-A6E4-4E51-B7CF-1E5C800A53EBQ36369648-E82B690D-D5ED-48E9-BA3E-FF8DE1D2ED1FQ37129235-E0CD8652-8545-4365-80D3-23D4C9F3CF27Q37254250-E952980B-3D9B-4E72-93F5-791F4B429CDCQ37411578-8E592D02-232F-4B70-83DB-DA392D8B130DQ38014923-A54CBB73-664A-495A-B1AD-BEFBF7EC97B5Q39013880-31B38610-5602-4082-986C-A1074C0F8035Q39113512-3A72E226-11BD-4758-BB85-C0D09A2C4071Q40694495-6D67B166-C007-4078-B551-FCF2D58D255EQ43930126-C25C4178-7752-4DFC-BEA1-2CC2AEC84E5EQ44606565-9E23166C-4785-4E01-92E2-9B9DB605C294Q45267606-3EFD4E66-756F-4FFC-8862-93DAB677828B
P2860
Antibody-targeted immunotherapy for treatment of malignancy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antibody-targeted immunotherapy for treatment of malignancy.
@ast
Antibody-targeted immunotherapy for treatment of malignancy.
@en
Antibody-targeted immunotherapy for treatment of malignancy.
@nl
type
label
Antibody-targeted immunotherapy for treatment of malignancy.
@ast
Antibody-targeted immunotherapy for treatment of malignancy.
@en
Antibody-targeted immunotherapy for treatment of malignancy.
@nl
prefLabel
Antibody-targeted immunotherapy for treatment of malignancy.
@ast
Antibody-targeted immunotherapy for treatment of malignancy.
@en
Antibody-targeted immunotherapy for treatment of malignancy.
@nl
P2093
P1476
Antibody-targeted immunotherapy for treatment of malignancy.
@en
P2093
A J Grillo-López
R L Weaver
P304
P356
10.1146/ANNUREV.MED.52.1.125
P577
2001-01-01T00:00:00Z